Moreover, the arylesterase (AE) activity of PON1 and the anti-oxidative (AO)-capacity of apoB-depleted serum were also lower in COVID-19 patients (p = 0.034, p < 0.001) when compared to non-COVID-19 pneumonia patients (Figure 1D,E). This evidence concerns the gene APOB and COVID-19.